Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lithium in ASD and Phelan-McDermid Syndrome (Lisphem)
NCT04623398Phase 3Completed
- Sponsor
- Assistance publique - Hôpitaux de Paris
- Start
- Feb 2022
- Primary completion
- Aug 2024
- Modality
- DNA Intercalators/Alkylators
- Countries
- 1
01
Overview
A Phase 3 trial of lithium carbonate in Autism Spectrum Disorder (ASD), Phelan-McDermid syndrome (PMS), sponsored by Assistance publique - Hôpitaux de Paris. Started Feb 2022; status: completed.
02
Drugs
lithium carbonate
03
Conditions
Autism Spectrum Disorder (ASD)Phelan-McDermid syndrome (PMS)
Beyond the preview
Go deeper on NCT04623398.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04623398.